I’ve been in this stock since 2020 and I’ve done a ton of research on their intranasal ketamine. Patent pending in the states, international patents in place. This is a dual enantiomer ketamine, low dose, non-invasive method of administration. Their stage 2 trial has wrapped up with readout expected mid-September of this year. Read: 3 years guaranteed exclusivity prior to patent approval.
There is hardly any volume in this stock. Almost a hundred institutions own shares and there are several more drugs in the pipeline including a patented version of trelahous for ALS. Am I missing something here? How is this so under the radar?
Leave a Reply